Abstract
Antimalarial drugs from different classes have demonstrated anticancer effects in different types of cancer cells, but their complete mode of action in cancer remains unknown. Recently, several studies reported the important role of palmitoyl-protein thioesterase 1 (PPT1), a lysosomal enzyme, as the molecular target of chloroquine and its derivates in cancer. It was also found that PPT1 is overexpressed in different types of cancer, such as breast, colon, etc. Our group has found a synergistic interaction between antimalarial drugs, such as mefloquine, artesunate and chloroquine and antineoplastic drugs in breast cancer cells, but the mechanism of action was not determined. Here, we describe the importance of autophagy and lysosomal inhibitors in tumorigenesis and hypothesize that other antimalarial agents besides chloroquine could also interact with PPT1 and inhibit the mechanistic target of rapamycin (mTOR) signalling, an important pathway in cancer progression. We believe that PPT1 inhibition results in changes in the lysosomal metabolism that result in less accumulation of antineoplastic drugs in lysosomes, which increases the bioavailability of the antineoplastic agents. Taken together, these mechanisms help to explain the synergism of antimalarial and antineoplastic agents in cancer cells.
Keywords: PPT1, antimalarial drugs, antineoplastic drugs, mTOR, autophagy, drug combination.
Graphical Abstract
Call for Papers in Thematic Issues
Innovative Therapeutic Approaches in Infectious Diseases
Infectious diseases continue to challenge global health systems due to rising antimicrobial resistance, emerging pathogens, and increasing drug tolerance. This special issue aims to move beyond traditional approaches by exploring innovative pharmacological strategies for the treatment of infectious diseases. We welcome original research and reviews ranging from clinical trials and ...read more
Pharmacokinetics of Nanocarriers: Challenges, Innovations, and Translational Perspectives
This thematic issue will focus on the evolving field of nanocarrier-based drug delivery systems and their pharmacokinetic behavior. Understanding the ADME (Absorption, Distribution, Metabolism, and Excretion) properties of nanoparticles is crucial for optimizing therapeutic efficacy and minimizing systemic toxicity. The issue will highlight the influence of nanocarrier physicochemical properties (size, ...read more
Unveil the Potential of Functional Framework Nucleic Acids in Theranostics
Nanomedicine demonstrates remarkable potential in disease diagnosis and treatment by precisely manipulating the physicochemical properties of materials on the nanometer scale. Its advantages as nanocarriers include high loading capacity, prolonged in vivo half-life and controllable targeted delivery. However, existing vectors (such as liposomes, polymers, and inorganic particles) still face significant ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
The Role of Nutraceuticals in Degenerative Diseases (Part 2)
Herb-Drug Interactions: A Medicinal Approach
The Role of Nutraceuticals in Degenerative Diseases (Part 1)
Brain Tumor Drug Development: Current Advances and Strategies (Part 2)
The Role of Asymmetric Synthesis in Drug Discovery
Brain Tumor Drug Development: Current Advances and Strategies (Part 1)
Handbook of Practical Pharmacology - I
Drug Repurposing for Antivirals
New Drugs Targeting Antibiotic-Resistant Bacteria: Recent Advances
Technical Advances in Pharmacy: An Overview
64